Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 3/20 | 0.76 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.64 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.62 |
| ▸ | MMP1 | P03956 | 5/20 | 0.61 |
| ▸ | MMP2 | P08253 | 5/20 | 0.61 |
| ▸ | MMP9 | P14780 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777283 | 1.00 | TRPM2 (0.76) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL8641486 | 0.88 | SMN1; SMN2 (0.73) | TRPM2TRPA1MMP1MMP2MMP9 | |
| SCHEMBL8641494 | 0.88 | SMN1; SMN2 (0.73) | TRPM2TRPA1MMP1MMP2MMP9 | |
| SCHEMBL2779276 | 0.86 | MMP1 (0.75) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL2779279 | 0.86 | MMP1 (0.75) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL6783841 | 0.86 | TRPA1 (0.77) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL6783845 | 0.86 | TRPA1 (0.77) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL294402 | 0.86 | TRPM2 (0.83) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL294403 | 0.86 | TRPM2 (0.83) | TRPM2TRPA1LTB4RTRPM8MMP1 | |
| SCHEMBL8064171 | 0.85 | GAA (0.59) | TRPM2TRPA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | claimed |
| EP-2649992-A1 | NEW PHARMACEUTIC USE OF BENZOIC AICD DERIVATIVES | Li, Xianliang (CN) | 2013-10-16 | — | — | EP | claimed |
| WO-2010071865-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2173167-A2 | TREATMENT OF NEUROPATHIC PAIN | Nuon Therapeutics, Inc. (US) | 2010-04-14 | — | — | EP | claimed |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) | 2010-02-18 | — | — | US | claimed |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM | 2009-12-17 | — | — | US | claimed |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | NUON THERAPEUTICS, INC. | 2009-08-06 | — | — | US | claimed |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS INC. | 2009-02-12 | — | — | US | claimed |
| WO-2009008997-A2 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| EP-1824469-A4 | A METHOD OF MODULATING B CELL FUNCTIONING | NUON THERAPEUTICS PTY LTD (AU) | 2008-07-30 | — | — | EP | claimed |
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | EBERHARD-KARLS-UNIVERSITAT TUBINGEN (DE) | 2008-05-01 | — | — | US | claimed |
| EP-1845967-A4 | A METHOD OF MODULATING T CELL FUNCTIONING | UNIV LELAND STANFORD JUNIOR (US) | 2008-03-05 | — | — | EP | claimed |
| EP-1885351-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Angiogen Pharmaceuticals Pty. Ltd (AU) | 2008-02-13 | — | — | EP | claimed |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2008-01-10 | — | — | US | claimed |
| EP-1845967-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | The Board of Trustees of Leland Stanford Junior University (US) | 2007-10-24 | — | — | EP | claimed |
| EP-1824469-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | Angiogen Pharmaceuticals Pty. Ltd (AU) | 2007-08-29 | — | — | EP | claimed |
| WO-2006122353-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) | 2006-11-23 | — | — | WO | claimed |
| WO-2006076580-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-07-20 | — | — | WO | claimed |
| WO-2006053390-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) | 2006-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | NLN, GAP43, CYBB | TRPM2 883/4885TRPA1 2236/4885LTB4R 114/4885 |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | NFATC1, GABRA5, GABRA6 | TRPM2 839/4885TRPA1 353/4885LTB4R 665/4885 |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | XDH, SLC10A1, SLC10A6 | TRPM2 1975/4885TRPA1 4098/4885LTB4R 2069/4885 |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | IFNG, CD4, IDO1 | TRPM2 949/4885TRPA1 901/4885LTB4R 57/4885 |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | OPRL1, OPRK1, ACHE | TRPM2 760/4885TRPA1 72/4885LTB4R 10/4885 |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | OPRL1, GAP43, AANAT | TRPM2 227/4885TRPA1 15/4885LTB4R 212/4885 |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | KYNU, IDO1, IDO2 | TRPM2 2273/4885TRPA1 1754/4885LTB4R 136/4885 |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | NLN, GAP43, CYBB | TRPM2 883/4885TRPA1 2236/4885LTB4R 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.